Is the Shingrix Shingles Vaccine an mRNA Vaccine?

Shingrix is not an mRNA vaccine. It is a recombinant subunit vaccine, meaning it contains a lab-produced piece of the varicella-zoster virus (a protein called glycoprotein E) paired with a specialized adjuvant that ramps up the immune response.¹ The confusion is understandable, given that Shingrix arrived on the scene around the same time COVID-19 mRNA vaccines did and that both represent newer vaccine technology compared to traditional live-virus shots. But the two platforms work in fundamentally different ways.

What Shingrix Actually Contains

Every dose of Shingrix delivers a purified version of glycoprotein E, a protein that sits on the surface of the varicella-zoster virus (VZV). This protein is manufactured using recombinant DNA technology in Chinese hamster ovary cells, a well-established system used to produce many biologic medicines. The protein itself cannot cause shingles or chickenpox because it is just one fragment of the virus, not the whole organism. When your immune system encounters this protein alongside the vaccine’s adjuvant, it learns to recognize VZV and mount a defense if the dormant virus reactivates later in life.²

This is a completely different approach from mRNA vaccines. An mRNA vaccine delivers a snippet of genetic instructions wrapped in a lipid nanoparticle. Your own cells read those instructions, temporarily produce the target protein, and then your immune system responds to it. With Shingrix, the protein is made in a factory and injected directly. Your cells never need to produce anything. The distinction matters because the manufacturing, storage, and immunological pathways differ between the two platforms, even if the end goal of both is training immunity against a specific protein.

The Adjuvant That Makes Shingrix Work

One reason Shingrix is so effective for an older population is its adjuvant system, called AS01B. mRNA vaccines generally do not need a traditional adjuvant because the lipid nanoparticle delivery system and the mRNA itself activate innate immune pathways. Shingrix, on the other hand, relies heavily on AS01B to wake up the immune system in a specific way.

AS01B is a liposome-based system that contains two immune-stimulating compounds. One is MPL (3-O-desacyl-4′-monophosphoryl lipid A), a detoxified derivative of bacterial endotoxin. The other is QS-21, a purified saponin molecule traditionally extracted from the bark of the Chilean soapbark tree.³ Together, these two ingredients trigger a burst of innate immune activity at the injection site, which primes the body to build strong, long-lasting antibody and T-cell responses to the glycoprotein E in the vaccine.⁴

This adjuvant system is also the reason Shingrix tends to cause more noticeable short-term side effects than many other vaccines people are used to, a point worth returning to later. The same adjuvant technology is used in GSK’s malaria vaccine (Mosquirix), so it has a track record beyond just shingles prevention.

Why the Confusion With mRNA Vaccines

Several things have blurred the line in public perception. First, timing. Shingrix was approved in the United States in 2017 and saw a big push for uptake among older adults in 2018 and 2019. The Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines arrived in late 2020. For many people, these were all part of the same wave of “new vaccines” that felt technologically unfamiliar. The language around them can also sound similar to a non-specialist ear: “recombinant,” “subunit,” “mRNA,” and “adjuvanted” all register as modern-sounding technical jargon.

Second, the side-effect profile of Shingrix feels similar to the early COVID-19 mRNA vaccine experience. Injection-site pain, fatigue, muscle aches, and headache are common after Shingrix, and some people experience a day or two of feeling genuinely run down. Because many adults had a similar experience with their COVID-19 mRNA shots, some assumed the mechanism must be the same. In reality, the strong reaction to Shingrix comes from its potent AS01B adjuvant stimulating the innate immune system, not from the mRNA-lipid-nanoparticle pathway.

Third, there is a real and growing field of mRNA-based herpes zoster vaccine research. Early-stage candidates have shown promising results in animal models, with at least one lyophilized mRNA vaccine candidate demonstrating strong immunogenicity and thermal stability in preclinical testing.⁵ Headlines about these experimental vaccines can easily lead someone to believe that the currently available shingles vaccine is already mRNA-based. It is not. No mRNA vaccine for shingles has been authorized for human use as of mid-2025.

How Effective Shingrix Is and Why That Matters for the Vaccine-Type Question

Shingrix’s effectiveness is one of the reasons it gets attention that sometimes feeds the confusion. In a large claims-based cohort study of U.S. adults aged 50 and older, the vaccine was about 86% effective overall at preventing shingles, with effectiveness holding at roughly 87% in people aged 50 to 79 and about 80% in those 80 and older.⁶ Those numbers are impressive for any vaccine given to older adults, whose immune systems are typically harder to stimulate.

This is a huge improvement over Zostavax, the older live-attenuated shingles vaccine that Shingrix replaced. A network meta-analysis found that in adults 60 and older, Shingrix had about 92% efficacy against shingles compared with roughly 51% for Zostavax. In people 70 and older, the gap was even wider: about 91% for Shingrix versus 37% for Zostavax.⁷ The recombinant-plus-adjuvant approach clearly outperforms the old live-virus strategy, which is part of why some people assume Shingrix must be using a next-generation platform like mRNA. It is next-generation, just a different branch of next-generation.

The durability of the immune response also sets Shingrix apart. Early comparisons showed that the older live vaccine’s efficacy dropped to around 40% within five years, while the recombinant vaccine maintained about 87% efficacy at four years, with stronger memory T-cell responses that may explain the longer-lasting protection.⁸

Side Effects and What They Tell You About the Vaccine Type

You might have heard that Shingrix “hits hard.” That reputation is earned. In pooled data from two large Phase 3 trials, about 78% of Shingrix recipients reported injection-site pain compared with 11% of those receiving a placebo. Muscle pain, fatigue, and headache were also common, reported by roughly 45%, 45%, and 38% of vaccine recipients, respectively.⁹ These reactions are temporary and reflect the adjuvant doing its job, firing up innate immunity so the adaptive immune system builds a strong, lasting response.

The reactogenicity profile is relevant to the vaccine-type question because it is driven by a completely different mechanism than the side effects of mRNA vaccines. With mRNA shots, the inflammatory response comes partly from the lipid nanoparticles and partly from the cellular production of the target protein. With Shingrix, it comes from MPL and QS-21 activating toll-like receptors and other innate immune pathways directly at the injection site.¹⁰ The end result feels similar to the person getting the shot, but the underlying biology is distinct.

Shingrix for Immunocompromised People

One practical advantage of Shingrix being a recombinant subunit vaccine rather than a live-virus vaccine is safety in immunocompromised individuals. The old Zostavax, which contained a weakened but live form of VZV, was contraindicated in people with compromised immune systems because the weakened virus could potentially cause disease. Shingrix contains no live virus at all, just a single protein plus the adjuvant.

This has opened up shingles prevention for populations that need it most. People on immunosuppressive medications, organ transplant recipients, and those with blood cancers face a much higher risk of shingles reactivation. Shingrix has been found to be safe in solid organ transplant recipients and is now recommended for all immunocompromised patients.¹¹ This is a population where the vaccine type genuinely matters: a live vaccine could be dangerous, an mRNA vaccine might behave unpredictably, but a well-studied recombinant protein with an established adjuvant is a known quantity.

Why Shingles Prevention Matters More With Age

Shingles is caused by the reactivation of VZV, the same virus that causes chickenpox. After a childhood chickenpox infection, the virus goes dormant in nerve cells and can stay quiet for decades. The immune system keeps it in check through cell-mediated immunity, but that immune surveillance weakens as people age. The incidence and severity of shingles, along with its most debilitating complication, postherpetic neuralgia, both increase with age as this cell-mediated immunity declines.¹² This is exactly why the adjuvant in Shingrix is so important. Older immune systems need a stronger nudge, and AS01B provides it.

Roughly one in three people who had chickenpox will develop shingles at some point in their life, and the risk climbs steeply after age 50. Postherpetic neuralgia, the burning nerve pain that can persist for months or years after the rash clears, is particularly common in people who develop shingles later in life. This is not a minor inconvenience; it can be severe enough to interfere with sleep, daily activities, and quality of life for extended periods.

The Two-Dose Schedule and Completion Rates

Shingrix requires two doses, typically given two to six months apart. This is a practical distinction from many mRNA vaccines, which initially launched as two-dose series but had much shorter intervals. Getting both Shingrix doses matters: the full two-dose course is what delivers the high efficacy numbers. Real-world data shows that about 70% of people who received a first dose completed the series within six months, rising to roughly 80% by twelve months.¹³

That 20% who never complete the series is a real gap in protection. Part of the dropout may be driven by the strong side effects after the first dose discouraging people from returning, and part may simply be scheduling inertia. If you have had your first Shingrix dose but have not returned for the second, it is worth going back even if the recommended window has passed. Guidelines generally allow for a delayed second dose without restarting the series.

Getting Shingrix Alongside Other Vaccines

Because Shingrix is given to the same age group that typically gets annual flu shots, pneumococcal vaccines, and sometimes COVID-19 boosters, a common question is whether it can be given at the same visit. An overview of co-administration data found that giving Shingrix alongside other routine adult vaccines does not meaningfully change the reactogenicity, immune response, or safety of either vaccine.¹⁴ In practice, this means you can get your flu shot and a Shingrix dose in the same appointment if the timing lines up, one in each arm.

The Future of mRNA Shingles Vaccines

While Shingrix is not an mRNA vaccine, the idea of an mRNA-based shingles vaccine is not fictional. Researchers are actively developing mRNA candidates for herpes zoster, and some have reached preclinical stages with encouraging results. The appeal is partly about manufacturing flexibility: mRNA vaccines can be designed and produced faster than recombinant protein vaccines, and they do not require a traditional adjuvant because the delivery system itself stimulates immunity.

There is also a supply-chain motivation. QS-21, the saponin in Shingrix’s adjuvant, has historically been sourced from the bark of the Chilean soapbark tree, which limits production volume.³ Researchers have recently achieved the complete biosynthesis of QS-21 in the lab, which could ease that bottleneck, but an mRNA platform would sidestep the issue entirely by not needing the adjuvant at all. One comparison study noted that while Shingrix performs excellently in clinical trials, QS-21’s dependence on a rare botanical source constrains production, giving mRNA approaches a potential manufacturing advantage.¹⁵

Whether an mRNA shingles vaccine will eventually reach the market depends on how it performs in human trials compared with Shingrix, which sets a high bar. A new vaccine would need to match or beat roughly 90% efficacy in older adults while maintaining an acceptable side-effect profile. For now, anyone getting vaccinated against shingles is receiving a recombinant protein vaccine with a well-characterized adjuvant, not an mRNA product. If that ever changes, the labeling and public health messaging will make the platform clear.